Drugmakers shelled out $25K to get into painkiller-approval summit

Pain-drug developers paid $25,000 to attend a closed summit meeting on clinical trials sufficient to win FDA approval, The Washington Post reports. The academics who ran the meeting, which was designed to gather information for developing agency guidelines for drug development, took a hard-sell approach, the Post reports, and drugmakers were eager to pay the freight for a chance to participate. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.